Equities

Towa Pharmaceutical Co Ltd

Towa Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)2,953.00
  • Today's Change19.00 / 0.65%
  • Shares traded60.70k
  • 1 Year change+67.40%
  • Beta0.6944
Data delayed at least 20 minutes, as of Jun 04 2024 07:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Towa Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of pharmaceuticals. The main products are generic drugs, which are launched after the efficacy and safety of new drugs have been confirmed for a certain period of time. It is a drug with the same effect, usage and dosage. The Company is involved in the sale and outsourced manufacture of products and generic drugs. The Company is involved in the research and outsourced manufacture of active pharmaceutical ingredient and soft capsules. The Company is also involved in the planning, development, contract manufacturing of health foods, general foods, miscellaneous goods and others.

  • Revenue in JPY (TTM)227.93bn
  • Net income in JPY16.17bn
  • Incorporated1957
  • Employees4.30k
  • Location
    Towa Pharmaceutical Co Ltd2-11, Shimbashi-choKADOMA-SHI 571-8580JapanJPN
  • Phone+81 669009100
  • Fax+81 669082138
  • Websitehttps://www.towayakuhin.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Eiken Chemical Co Ltd40.05bn2.63bn80.82bn754.0029.731.5818.912.0270.5270.521,080.891,328.720.62622.833.40--4.128.015.0610.1441.7645.926.5811.502.62--0.086235.21-7.442.29-54.08-5.2411.6611.20
Zeria Pharmaceutical Co Ltd75.73bn7.73bn105.55bn1.73k11.331.107.881.39175.39175.391,717.901,806.330.53041.483.99--5.393.898.396.2873.2971.9310.167.570.794613.040.366735.0010.744.1424.7817.4920.775.29
Torii Pharmaceutical Co Ltd56.28bn5.29bn109.01bn583.0020.130.893618.981.94188.05188.052,002.444,235.560.42882.722.2596,531,740.004.036.524.447.3544.8349.559.4017.985.58--0.0024.1711.74-2.674.4428.76-20.3820.11
GNI Group Ltd27.75bn9.55bn110.11bn843.0011.713.189.283.97188.10188.10554.62693.410.55692.017.8932,921,710.0022.457.2326.738.8084.7885.7540.3214.572.7430.590.14170.0049.3238.971,981.71--19.69--
Kyorin Pharmaceutical Co Ltd119.53bn5.32bn110.80bn2.14k18.500.753312.960.92792.7092.702,082.822,276.510.67591.342.61--3.013.053.903.7943.0147.114.454.761.45--0.13866.815.531.0212.68-4.987.41-7.06
Mochida Pharmaceutical Co Ltd102.89bn4.55bn113.53bn1.53k23.990.839417.461.10126.33126.332,868.813,609.640.64781.863.28--2.864.373.445.3150.6152.474.426.713.31----44.88-0.3641-1.26-31.61-11.6310.91-1.21
Sumitomo Pharma Co Ltd314.56bn-314.97bn121.36bn6.25k--0.7764--0.3858-792.79-792.79791.76392.820.3081.213.76---30.84-5.07-54.58-7.7359.7669.99-100.12-12.280.2992--0.7285---43.38-7.29-322.71--4.02--
Takara Bio Inc43.51bn1.48bn123.19bn1.79k83.231.1019.162.8312.2912.29361.29926.000.34741.453.71--1.2110.061.3211.3861.8564.393.4718.847.10--0.008627.55-44.333.95-90.76-16.5516.1819.42
Nxera Pharma Co Ltd16.43bn-9.07bn130.54bn350.00--1.97--7.94-107.30-107.30194.96736.600.1309--5.7746,954,280.00-7.23-0.6588-7.78-0.703674.4489.83-55.20-4.464.03-10.910.5238---18.00---1,982.98------
Towa Pharmaceutical Co Ltd227.93bn16.17bn148.88bn4.30k8.800.91256.020.6532328.58328.584,630.883,167.260.56841.513.66--4.034.215.035.6335.7039.237.107.231.46--0.564920.799.1316.74634.803.7228.2010.86
Kissei Pharmaceutical Co Ltd75.58bn11.16bn155.08bn1.80k12.760.63199.982.05246.57246.571,669.954,977.430.31351.562.94--4.683.615.053.9049.4149.4714.9412.694.43--0.00634.6911.980.89196.0015.286.5810.40
KAKEN PHARMACEUTICAL CO., LTD.72.04bn8.03bn164.23bn1.13k16.800.941818.762.28212.76212.761,909.113,796.040.42642.053.37--4.756.835.407.8753.4954.7811.1414.484.72--0.026151.19-1.29-5.2147.52-14.700.36390.00
Nippon Shinyaku Co., Ltd.148.25bn25.85bn215.88bn2.19k8.010.93986.991.46383.80383.802,201.163,269.710.5921.333.25--10.3210.4512.0912.3166.1261.2717.4416.473.35--0.012932.622.835.2613.329.6645.9312.12
Data as of Jun 04 2024. Currency figures normalised to Towa Pharmaceutical Co Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

14.45%Per cent of shares held by top holders
HolderShares% Held
Brown Capital Management LLCas of 31 Dec 20231.83m3.55%
Guardians of New Zealand Superannuationas of 30 Jun 20231.01m1.96%
The Vanguard Group, Inc.as of 09 May 2024975.88k1.89%
Nomura Asset Management Co., Ltd.as of 30 Apr 2024948.10k1.84%
Dimensional Fund Advisors LPas of 09 May 2024554.36k1.08%
Norges Bank Investment Managementas of 31 Dec 2023525.54k1.02%
Nikko Asset Management Co., Ltd.as of 10 May 2024456.00k0.89%
Daiwa Asset Management Co. Ltd.as of 30 Apr 2024429.60k0.83%
Argenta Spaarbank NVas of 30 Jun 2023387.00k0.75%
BlackRock Fund Advisorsas of 09 May 2024324.80k0.63%
More ▼
Data from 30 Jun 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.